You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameArdeparin
Accession NumberDB00407  (APRD00803)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionArdeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.
Structure
Thumb
Synonyms
Ardeparin sodium
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NormifloWyeth-Ayerst (United States)
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV5T10N50RD
CAS number9041-08-1
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFor prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.
Structured Indications Not Available
PharmacodynamicsArdeparin, an anticoagulant, is a fractionated heparin. It acts at multiple sites in the normal coagulation system to inhibit reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo.
Mechanism of actionArdeparin binds to antithrombin III, accelerating its activity in inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity versus anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Antithrombin-IIIProteinyes
potentiator
HumanP01008 details
Heparin cofactor 2Proteinyes
agonist
HumanP05546 details
Related Articles
AbsorptionWell absorbed following subcutaneous administration, with a mean bioavailability of 92% (based on anti-factor Xa activity).
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Liver and the reticulo-endothelial system are the sites of biotransformation.

Route of eliminationNot Available
Half lifeElimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.
ClearanceNot Available
ToxicitySymptoms of overdose may include excessive bleeding and bruising.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Enoxaparin Action PathwayDrug actionSMP00272
Ardeparin Action PathwayDrug actionSMP00275
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Ardeparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Ardeparin.Approved
AcenocoumarolArdeparin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Ardeparin.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Ardeparin.Approved
AliskirenArdeparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Allylestrenol.Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Ardeparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Ardeparin.Approved
AltrenogestThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Ardeparin.Investigational
AmilorideArdeparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Ardeparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Ardeparin.Approved
AncrodArdeparin may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Ardeparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Ardeparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Ardeparin.Approved
Antithrombin III humanArdeparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Ardeparin.Approved
ApremilastApremilast may increase the anticoagulant activities of Ardeparin.Approved, Investigational
AprotininThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Ardeparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Ardeparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Ardeparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Ardeparin.Approved
Azilsartan medoxomilArdeparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ardeparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Ardeparin.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Ardeparin.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Ardeparin.Approved
BenazeprilArdeparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Ardeparin.Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Ardeparin.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Ardeparin.Investigational
BivalirudinBivalirudin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
BromfenacBromfenac may increase the anticoagulant activities of Ardeparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Ardeparin.Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Ardeparin.Investigational
CanagliflozinArdeparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanArdeparin may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilArdeparin may increase the hyperkalemic activities of Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Ardeparin.Approved
CaptoprilArdeparin may increase the hyperkalemic activities of Captopril.Approved
CarprofenCarprofen may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Ardeparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
CertoparinArdeparin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Ardeparin.Withdrawn
CilazaprilArdeparin may increase the hyperkalemic activities of Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Ardeparin.Approved
Citric AcidArdeparin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Ardeparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Ardeparin.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Ardeparin is combined with Collagenase.Approved
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Ardeparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Ardeparin.Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Ardeparin.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Ardeparin.Approved
DalteparinArdeparin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidArdeparin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Ardeparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ardeparin is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Ardeparin.Investigational
DesirudinArdeparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Ardeparin.Investigational
DesogestrelThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Desogestrel.Approved
DextranArdeparin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ardeparin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ardeparin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ardeparin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Ardeparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Ardeparin.Approved
DienogestThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Ardeparin.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Ardeparin.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Ardeparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Ardeparin.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Ardeparin.Investigational
DydrogesteroneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E6201E6201 may increase the anticoagulant activities of Ardeparin.Investigational
EbselenEbselen may increase the anticoagulant activities of Ardeparin.Investigational
Edetic AcidArdeparin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Ardeparin.Approved
EnalaprilArdeparin may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatArdeparin may increase the hyperkalemic activities of Enalaprilat.Approved
EnoxaparinArdeparin may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Ardeparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Ardeparin.Approved
EplerenoneArdeparin may increase the hyperkalemic activities of Eplerenone.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Ardeparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ardeparin.Approved
EprosartanArdeparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Ardeparin.Approved, Vet Approved
EstroneEstrone may decrease the anticoagulant activities of Ardeparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Ardeparin.Approved
Ethyl biscoumacetateArdeparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Ardeparin.Approved
EtonogestrelThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Ardeparin.Approved
exisulindexisulind may increase the anticoagulant activities of Ardeparin.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Ardeparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Ardeparin.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Ardeparin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
FluindioneArdeparin may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Ardeparin.Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational
FondaparinuxArdeparin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumArdeparin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanArdeparin may increase the hyperkalemic activities of Forasartan.Experimental
FosinoprilArdeparin may increase the hyperkalemic activities of Fosinopril.Approved
GabexateArdeparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Ardeparin.Investigational
GestodeneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestrinone.Approved
HeminHemin may increase the anticoagulant activities of Ardeparin.Approved
HeparinArdeparin may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Ardeparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Ardeparin.Investigational
HirulogArdeparin may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Ardeparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ardeparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Ardeparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Ardeparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Ardeparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Ardeparin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ardeparin.Approved, Nutraceutical
idraparinuxArdeparin may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Ardeparin.Approved, Investigational
ImidaprilArdeparin may increase the hyperkalemic activities of Imidapril.Investigational
IndobufenIndobufen may increase the anticoagulant activities of Ardeparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Ardeparin.Withdrawn
IrbesartanArdeparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Ardeparin.Withdrawn
Kct 0809Kct 0809 may increase the anticoagulant activities of Ardeparin.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Ardeparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Ardeparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Ardeparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Ardeparin.Approved
LevonorgestrelThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ardeparin.Approved
LisinoprilArdeparin may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Ardeparin.Investigational
LornoxicamLornoxicam may increase the anticoagulant activities of Ardeparin.Approved
LosartanArdeparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Ardeparin.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
LynestrenolThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Ardeparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Ardeparin.Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Ardeparin.Approved
Megestrol acetateThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ardeparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Ardeparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Ardeparin.Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Ardeparin.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Ardeparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Ardeparin.Investigational
MoexiprilArdeparin may increase the hyperkalemic activities of Moexipril.Approved
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Ardeparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Ardeparin.Approved
NadroparinArdeparin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Ardeparin.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Ardeparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Ardeparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
NCX 4016NCX 4016 may increase the anticoagulant activities of Ardeparin.Investigational
NepafenacNepafenac may increase the anticoagulant activities of Ardeparin.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Ardeparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Ardeparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Ardeparin.Investigational
NomegestrolThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Norethisterone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Ardeparin is combined with Obinutuzumab.Approved
OlmesartanArdeparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Ardeparin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ardeparin.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Ardeparin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatArdeparin may increase the hyperkalemic activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Ardeparin.Approved
OrgoteinOrgotein may increase the anticoagulant activities of Ardeparin.Vet Approved
OtamixabanArdeparin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Ardeparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Ardeparin.Withdrawn
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Ardeparin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Ardeparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Ardeparin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Ardeparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PerindoprilArdeparin may increase the hyperkalemic activities of Perindopril.Approved
PhenindioneArdeparin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonArdeparin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Ardeparin.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Ardeparin.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Ardeparin.Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Ardeparin.Approved
ProgesteroneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Ardeparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Ardeparin.Approved
Protein CArdeparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanArdeparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeArdeparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Ardeparin.Investigational
QuinaprilArdeparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Ardeparin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ardeparin.Investigational
RamiprilArdeparin may increase the hyperkalemic activities of Ramipril.Approved
RescinnamineArdeparin may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Ardeparin.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Ardeparin.Approved
ReviparinArdeparin may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Ardeparin.Approved
RivaroxabanArdeparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Ardeparin.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Ardeparin.Approved, Investigational
S EquolS Equol may decrease the anticoagulant activities of Ardeparin.Investigational
SacubitrilArdeparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Ardeparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Ardeparin.Approved
SaprisartanArdeparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinArdeparin may increase the hyperkalemic activities of Saralasin.Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Ardeparin.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Ardeparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Ardeparin.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Ardeparin.Approved, Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
SpiraprilArdeparin may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneArdeparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Ardeparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Ardeparin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Ardeparin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ardeparin.Approved
SulindacSulindac may increase the anticoagulant activities of Ardeparin.Approved
SulodexideArdeparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ardeparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ardeparin.Approved
TasosartanArdeparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanArdeparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemocaprilArdeparin may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Ardeparin.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Ardeparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Ardeparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Ardeparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Ardeparin.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Ardeparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Ardeparin.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Ardeparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Ardeparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Ardeparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Ardeparin.Approved
TipranavirTipranavir may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Ardeparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Ardeparin.Approved
TolmetinTolmetin may increase the anticoagulant activities of Ardeparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ardeparin is combined with Tositumomab.Approved
TrandolaprilArdeparin may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ardeparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TriamtereneArdeparin may increase the hyperkalemic activities of Triamterene.Approved
TriflusalTriflusal may increase the anticoagulant activities of Ardeparin.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Ardeparin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Ardeparin.Investigational, Withdrawn
ValsartanArdeparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Ardeparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Ardeparin.Approved
WarfarinArdeparin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranArdeparin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Ardeparin may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Ardeparin.Approved
ZeranolZeranol may decrease the anticoagulant activities of Ardeparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Ardeparin.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 20:12.04.16
  • 92:00.00
PDB Entries
FDA labelNot Available
MSDSDownload (65.5 KB)
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
Manufacturers
  • Wyeth ayerst laboratories
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Gene Name:
SERPINC1
Uniprot ID:
P01008
Molecular Weight:
52601.935 Da
References
  1. Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367 ]
  2. Lin P, Sinha U, Betz A: Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. Biochim Biophys Acta. 2001 Apr 3;1526(1):105-13. [PubMed:11287128 ]
  3. Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995 Aug 15;86(4):1368-73. [PubMed:7632944 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
Gene Name:
SERPIND1
Uniprot ID:
P05546
Molecular Weight:
57070.16 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23